Link to this page
National Cancer Institute Thesaurus
Last uploaded:
February 23, 2024
Jump to:
| Preferred Name | Basiliximab | |
| Synonyms |
BASILIXIMAB Basiliximab SDZ-CHI-621 Simulect |
|
| Definitions |
A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C52186 |
|
| CAS_Registry |
179045-86-4
|
|
| code |
C52186
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 |
|
| Contributing_Source |
CTRP FDA
|
|
| DEFINITION |
A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes.
|
|
| Display_Name |
Basiliximab
|
|
| FDA_UNII_Code |
9927MT646M
|
|
| FULL_SYN |
BASILIXIMAB Basiliximab SDZ-CHI-621 Simulect
|
|
| Has_Target | ||
| label |
Basiliximab
|
|
| Legacy Concept Name |
Basiliximab
|
|
| NCI_Drug_Dictionary_ID |
459956
|
|
| PDQ_Closed_Trial_Search_ID |
459956
|
|
| PDQ_Open_Trial_Search_ID |
459956
|
|
| Preferred_Name |
Basiliximab
|
|
| prefixIRI |
Thesaurus:C52186
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C0676831
|
|
| subClassOf |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping